


1. (Thrice Amended) A compound of formula (I)



or a pharmaceutically acceptable derivative thereof wherein

D1
R⁰ and R¹ are independently selected from the group consisting of H, halogen, C₁-alkyl, C₁-alkoxy, and C₁-alkoxy substituted by one or more fluorine atoms;

R² is selected from the group consisting of H, C₁-alkyl, C₁-alkyl substituted by one or more fluorine atoms, C₁-alkoxy, C₁-hydroxyalkyl, SC₁-alkyl, C(O)H, C(O)C₁-alkyl, C₁-alkylsulphonyl, and C₁-alkoxy substituted by one or more fluorine atoms; and

R³ is C₁-alkyl or NH₂.

2. (Twice Amended) A compound as claimed in claim 1 wherein R⁰ and R¹ are independently selected from the group consisting of H, halogen, C₁-alkyl, and C₁-alkoxy; R² is C₁-alkyl substituted by one or more fluorine atoms; and R³ is C₁-alkyl or NH₂.

3. (Twice Amended) A compound as claimed in claim 1 wherein R⁰ and R¹ are independently selected from the group consisting of H, F, Cl, C₁-alkyl, and C₁-alkoxy; R² is C₁-alkyl substituted by one or more fluorine atoms; and R³ is methyl or NH₂.

4. (Twice Amended) A compound as claimed in claim 1 wherein R⁰ is selected from the group consisting of F, Cl, C₁-alkyl and C₁-alkoxy; R¹ is H; R² is C₁-alkyl substituted by one or more fluorine atoms; and R³ is methyl or NH₂.

5. (Twice Amended) A compound as claimed in claim 1 wherein R⁰ is at the 3- or 4- position of the phenyl ring; and R² is at the 6- position of the pyridine ring.

6. (Twice Amended) A compound selected from the group consisting of:

4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-
benzenesulfonamide;

2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-
a]pyridine;

4-[2-(4-ethoxy-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-
benzenesulfonamide;

4-[2-(4-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-
benzenesulfonamide;

2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-
a]pyridine;

4-(2-phenyl-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl)-benzenesulfonamide;

3-(4-methanesulfonyl-phenyl)-2-phenyl-6-trifluoromethyl-pyrazolo[1,5-a]pyridine;

4-[2-(4-methyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-
benzenesulfonamide;

or a pharmaceutically acceptable derivative thereof.

7. (Amended) A compound selected from the group consisting of:

N-acetyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-
yl]benzenesulfonamide;

N-acetyl-4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-
yl]benzenesulfonamide;

N-acetyl-4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-
yl]benzenesulfonamide;

sodium salt of N-acetyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-
3-yl]benzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-
methoxyacetyl)benzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-
propionylbenzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-isobutyrylbenzenesulfonamide;
N-benzoyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
methyl 4-[[{4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonyl]amino]-4-oxobutanoate;
4-[[{4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonyl]amino]-4-oxobutanoic acid;
4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentanoylbenzenesulfonamide;
2-[[{4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonyl]amino]-2-oxoethyl acetate;
N-acetyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
N-(2-chloroacetyl)-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
N-[2-(diethylamino)acetyl]-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
methyl {4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonylcarbamate; and
tert-butyl {4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonylcarbamate.


8. (Amended) A compound selected from the group consisting of:

4-[6-chloro-2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
6-chloro-2-(3-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
4-[6-methyl-2-phenyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(3-fluorophenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(3-ethoxyphenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(4-ethoxyphenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;


6-methyl-2-phenyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(3-fluorophenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(3-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(4-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
or a pharmaceutically acceptable derivative thereof.

9. (Twice Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) reacting a compound of formula (II)



or a protected derivative thereof, with a compound of formula (III)



or a protected derivative thereof to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

10. (Twice Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

11. (Twice Amended) A method of treating an animal subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound claimed in claim 1.


12

17. (New) The compound according to claim 1, wherein R^0 is selected from the group consisting of F, Cl, methyl and ethoxy; R^1 is H; R^2 is trifluoromethyl; and R^3 is methyl or NH_2 .

13

18. (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R^3 represents C_{1-4} alkyl, reacting a compound of formula (IV)




or a protected derivative thereof with an oxidising agent to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

14

19. (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R^2 is C_{1-6} alkylsulphonyl, oxidising a compound of formula (V)




or a protected derivative thereof to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

¹⁵
~~20.~~ (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R² is C₁₋₆alkoxy substituted by one or more fluorine atoms, reacting a alcohol of formula (VI)




or a protected derivative thereof with a halofluoroalkane to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

¹⁶
~~21.~~ (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R³ is NH₂, reacting a compound of formula (X)



with a source of ammonia under conventional conditions to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

22. 17 (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) interconverting a compound of formula (I) into another compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

23. 18 (Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) deprotecting a protected derivative of compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable derivative thereof.

25. 19 (Amended) A method for the prophylaxis or treatment of a human subject suffering from an inflammatory disorder, which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.

28. 20 (Twice Amended) A method for the prophylaxis or treatment of a human subject suffering from a condition or disease selected from the group consisting of pain, fever and inflammation, said method comprising administering an effective amount of a compound as claimed in claim 1.

27. 21 (Amended) The method according to claim *28. 20*, wherein said condition or disease is selected from the group consisting of rheumatic fever, symptoms associated

with influenza or other viral infections, lower back pain, neck pain, headache, toothache, sprains, strains, myositis, neuropathic pain, synovitis, arthritis, rheumatoid arthritis, degenerative joint diseases, osteoarthritis, gout, ankylosing spondylitis, tendinitis, bursitis, psoriasis, eczema, burns, dermatitis, sports injuries, injuries arising from surgical procedures and injuries arising from dental procedures.

22
28. (Twice Amended) A method for the prophylaxis or treatment of a human subject suffering from pain, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1.

23
29. (Twice Amended) A method for the prophylaxis or treatment of a human subject suffering from arthritis, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1.

24
30. (Amended) A method for the prophylaxis and treatment of a human subject suffering from a condition involving inflammatory processes, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1, wherein said condition involving inflammatory processes are selected from the group consisting of asthma, allergic rhinitis, respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, conjunctivitis and myocardial ischemia.

25
31. (Amended) A method for the prophylaxis or treatment of a human subject suffering from a cognitive disorder, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1.

26
32. (Amended) The method of claim 31 wherein said cognitive disorder is selected from the group consisting of degenerative dementia, senile dementia, Alzheimer's disease, Pick's disease, Huntington's chorea, Parkinson's disease, Creutzfeldt-Jakob disease,

*Del
cancel*

vascular dementia, multi-infarct dementia, dementia associated with intracranial space occupying lesions, trauma, infections, metabolism, toxins, anoxia, and vitamin deficiency; and mild cognitive impairment associated with aging.

²⁷
~~33.~~ (New) The method of claim ²⁵~~31~~, wherein said cognitive disorder is dementia.

²⁸
~~34.~~ (New) The method of claim ²⁵~~31~~, wherein said cognitive disorder is Alzheimer's disease.

²⁹
~~35.~~ (New) 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide.
